These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8098057)

  • 1. Successful re-treatment with taxol after major hypersensitivity reactions.
    Peereboom DM; Donehower RC; Eisenhauer EA; McGuire WP; Onetto N; Hubbard JL; Piccart M; Gianni L; Rowinsky EK
    J Clin Oncol; 1993 May; 11(5):885-90. PubMed ID: 8098057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premedication strategy for weekly paclitaxel.
    Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
    Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersensitivity reaction to paclitaxel: nursing interventions.
    Myers JS
    Clin J Oncol Nurs; 2000; 4(4):161-3. PubMed ID: 11261096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
    Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
    Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
    Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
    Jao ME; Indorf AL; Segal EM; Miske A; Eaton KD; Marsolini T; Ghuman S
    J Oncol Pharm Pract; 2024 Jan; 30(1):105-111. PubMed ID: 37021579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
    Kobierski J; Majdak E; Mielcarek P; Emerich J
    Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
    Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
    J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    J Clin Oncol; 2000 Jan; 18(1):102-5. PubMed ID: 10623699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
    Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
    Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose dexamethasone paclitaxel premedication.
    Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
    Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine-2 (H
    Foreman E; Polwart C; Walker A; Chambers P
    Br J Clin Pharmacol; 2022 Sep; 88(9):4191-4198. PubMed ID: 35470452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
    Lansinger OM; Biedermann S; He Z; Colevas AD
    J Clin Oncol; 2021 Nov; 39(32):3583-3590. PubMed ID: 34357780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis for paclitaxel hypersensitivity reactions.
    Kintzel PE
    Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxol hypersensitivity: rapid retreatment is safe and cost effective.
    Olson JK; Sood AK; Sorosky JI; Anderson B; Buller RE
    Gynecol Oncol; 1998 Jan; 68(1):25-8. PubMed ID: 9454655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.
    Chen FC; Wang LH; Zheng XY; Zhang XM; Zhang J; Li LJ
    Oncotarget; 2017 Mar; 8(12):19236-19243. PubMed ID: 27911278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
    Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
    Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.
    Barroso-Sousa R; Vaz-Luis I; Di Meglio A; Hu J; Li T; Rees R; Sinclair N; Milisits L; Leone JP; Constantine M; Faggen M; Briccetti F; Block C; Partridge A; Burstein H; Waks AG; Tayob N; Trippa L; Tolaney SM; Hassett MJ; Winer EP; Lin NU
    Oncologist; 2021 Nov; 26(11):927-933. PubMed ID: 34472667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
    Feldweg AM; Lee CW; Matulonis UA; Castells M
    Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
    Yahata H; Saito M; Sendo T; Itoh Y; Uchida M; Hirakawa T; Nakano H; Oishi R
    Int J Cancer; 2006 May; 118(10):2636-8. PubMed ID: 16353140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.